Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: ANIP AMPH IRWD PRGO VTRS

| Held by: AVUV XBI VTI IWM FNDA VXF IWN CALF IBB DFAT

Index	RUT	P/E	-	EPS (ttm)	-0.28	Insider Own	5.60%	Shs Outstand	51.80M	Perf Week	12.30%
Market Cap	471.08M	Forward P/E	10.03	EPS next Y	0.91	Insider Trans	-2.95%	Shs Float	48.71M	Perf Month	13.70%
Enterprise Value	944.58M	PEG	-	EPS next Q	-0.09	Inst Own	85.51%	Short Float	20.07%	Perf Quarter	-16.70%
Income	-8.60M	P/S	0.70	EPS this Y	-78.76%	Inst Trans	-0.77%	Short Ratio	11.07	Perf Half Y	0.55%
Sales	676.80M	P/B	0.90	EPS next Y	180.00%	ROA	-0.63%	Short Interest	9.78M	Perf YTD	-26.13%
Book/sh	10.10	P/C	2.92	EPS next 5Y	-	ROE	-1.60%	52W High	14.06 -35.06%	Perf Year	42.66%
Cash/sh	3.13	P/FCF	3.48	EPS past 3/5Y	- -30.38%	ROIC	-0.78%	52W Low	5.61 62.60%	Perf 3Y	11.75%
Dividend Est.	-	EV/EBITDA	5.67	Sales past 3/5Y	-12.72% -13.74%	Gross Margin	44.44%	Volatility	4.73% 5.79%	Perf 5Y	-84.11%
Dividend TTM	-	EV/Sales	1.40	EPS Y/Y TTM	93.33%	Oper. Margin	10.52%	ATR (14)	0.46	Perf 10Y	-77.60%
Dividend Ex-Date	-	Quick Ratio	2.08	Sales Y/Y TTM	-29.89%	Profit Margin	-1.27%	RSI (14)	60.46	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.29	EPS Q/Q	-93.74%	SMA20	7.12%	Beta	2.32	Target Price	12.00
Payout	0.00%	Debt/Eq	1.21	Sales Q/Q	-29.75%	SMA50	9.50%	Rel Volume	1.23	Prev Close	8.45
Employees	900	LT Debt/Eq	1.11	Earnings	Apr 30 AMC	SMA200	-6.35%	Avg Volume	882.97K	Price	9.13
IPO	Nov 15, 2006	Option/Short	Yes / Yes	EPS/Sales Surpr.	184.00% 7.66%	Trades		Volume	1,081,651	Change	8.05%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-30-24	Initiated	H.C. Wainwright	Buy	$15
Aug-22-24	Initiated	Rodman & Renshaw	Buy	$16
Mar-07-24	Upgrade	The Benchmark Company	Hold → Buy	$5
Nov-20-23	Resumed	JP Morgan	Underweight
Aug-29-23	Downgrade	The Benchmark Company	Buy → Hold
Apr-10-23	Upgrade	The Benchmark Company	Hold → Buy	$22
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight	$23 → $9
Nov-10-22	Downgrade	The Benchmark Company	Buy → Hold
Apr-29-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-20-22	Upgrade	The Benchmark Company	Hold → Buy	$77
Nov-08-21	Downgrade	The Benchmark Company	Buy → Hold
May-05-21	Downgrade	Argus	Buy → Hold
Apr-07-21	Initiated	The Benchmark Company	Buy	$150
Feb-24-21	Upgrade	Chardan Capital Markets	Neutral → Buy	$112
Feb-19-21	Downgrade	Chardan Capital Markets	Buy → Neutral	$112
Jan-08-21	Downgrade	Wells Fargo	Overweight → Equal Weight	$110
Sep-14-20	Resumed	JP Morgan	Neutral	$103
Jul-31-20	Reiterated	Chardan Capital Markets	Buy	$86 → $112
Sep-12-19	Initiated	Guggenheim	Buy
Sep-04-19	Upgrade	Wells Fargo	Market Perform → Outperform

Show Previous Ratings

May-20-26 07:30AM	Emergent BioSolutions to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-18-26 08:59AM	Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000 [Smallpox and Mpox (Vaccinia) Vaccine, Live] (GlobeNewswire)
May-01-26 08:30AM	Emergent BioSolutions Inc. Q1 2026 Earnings Call Summary (Moby)
03:19AM	Emergent BioSolutions Inc (EBS) Q1 2026 Earnings Call Highlights: Strong Revenue and Strategic ... (GuruFocus.com)
Apr-30-26 05:20PM	Emergent Biosolutions: Q1 Earnings Snapshot (Associated Press)
04:30PM	Loading…
04:30PM	Emergent BioSolutions Reports First Quarter 2026 Financial Results (GlobeNewswire)
07:55AM	Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox (GlobeNewswire)
Apr-29-26 07:35AM	Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142 (GlobeNewswire)
06:53AM	Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN Nasal Spray Among Canadians and Help Save Lives (GlobeNewswire)
Apr-28-26 08:01AM	Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States (GlobeNewswire)
Apr-16-26 04:05PM	Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026 (GlobeNewswire)
04:05PM	Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility (GlobeNewswire)
Apr-09-26 04:25PM	Emergent BioSolutions Partners with British Columbia to Supply NARCAN Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program (GlobeNewswire) -5.80%
02:34PM	McKinsey Will Add $125 Million to Purdue's $7 Billion Bankruptcy Settlement (Moby)
Apr-07-26 08:05AM	Emergent BioSolutions Launches New NARCAN Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness (GlobeNewswire)
08:00AM	Loading…
Apr-02-26 08:00AM	Emergent BioSolutions Participates in Upcoming International Preparedness Conferences (GlobeNewswire)
Mar-25-26 04:15PM	Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures (GlobeNewswire)
Mar-17-26 12:49PM	Mpox Is on the Rise in the U.S. 3 Vaccine Stocks Worth a Second Look. (Barrons.com)
Mar-03-26 08:00AM	Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors (GlobeNewswire)
Feb-28-26 01:07AM	Emergent Biosolutions Q4 Earnings Call Highlights (MarketBeat)
Feb-27-26 02:43AM	Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today? (New feeds test provider finance) -26.58%
12:04AM	Emergent BioSolutions Inc (EBS) Q4 2025 Earnings Call Highlights: Strategic Gains Amid Revenue ... (GuruFocus.com)
Feb-26-26 04:58PM	Emergent Biosolutions: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
04:01PM	Emergent BioSolutions Announces New $50 Million Stock Repurchase Program (GlobeNewswire)
04:01PM	Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness (GlobeNewswire)
Feb-13-26 07:55AM	Emergent BioSolutions Wins FDA Approval For New Narcan Multipacks To Expand Overdose Access (Benzinga)
Feb-12-26 06:00PM	Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN Nasal Spray Multipacks (GlobeNewswire)
09:02AM	Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Jan-16-26 10:26AM	?Emergent BioSolutions (EBS) Receives a New Order from US Department of War (Insider Monkey)
07:46AM	Loading…
07:46AM	Dirty Vaccines, Clean Cash: Emergent Ex-CEO Sued For Insider Trading (Benzinga)
06:24AM	Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading (BioPharma Dive)
Jan-15-26 01:08PM	NY Attorney General Sues Former Emergent BioSolutions CEO for Insider Trading (The Wall Street Journal) -12.68%
Jan-14-26 08:00AM	Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness (GlobeNewswire)
Jan-12-26 07:30AM	Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation (GlobeNewswire)
Jan-08-26 04:30PM	Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026 (GlobeNewswire)
08:00AM	Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa (GlobeNewswire)
Jan-07-26 07:59AM	Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 (GlobeNewswire) +5.70%
Dec-12-25 08:30AM	Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site (GlobeNewswire)
Dec-04-25 11:30AM	Qiagen (QGEN) Up 6.3% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-18-25 08:00AM	Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access (GlobeNewswire)
Nov-12-25 04:01PM	Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors (GlobeNewswire)
09:15AM	Black Diamond Therapeutics, Inc. (BDTX) Hits Fresh High: Is There Still Room to Run? (Zacks)
Nov-07-25 08:55AM	Looking for a Fast-paced Momentum Stock at a Bargain? Consider Emergent Biosolutions (EBS) (Zacks)
Oct-31-25 09:15AM	Emergent Biosolutions Inc. (EBS) Soars to 52-Week High, Time to Cash Out? (Zacks)
Oct-30-25 04:08PM	Emergent BioSolutions Inc (EBS) Q3 2025 Earnings Call Highlights: Surpassing Revenue ... (GuruFocus.com) +36.60%
Oct-29-25 06:05PM	Emergent Biosolutions (EBS) Beats Q3 Earnings and Revenue Estimates (Zacks)
05:01PM	Emergent Biosolutions: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Emergent BioSolutions Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-28-25 08:00AM	Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness (GlobeNewswire)
Oct-08-25 07:45AM	Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025 (GlobeNewswire)
Sep-24-25 04:05PM	Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone (GlobeNewswire) +5.43%
02:05PM	3 Small-Cap Stocks to Watch After the Fed's Rate Cuts (MarketBeat)
Sep-19-25 08:34AM	Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner (GlobeNewswire)
Sep-15-25 08:35AM	Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain (GlobeNewswire)
Sep-09-25 12:10PM	US Government signs $56m smallpox/mpox vaccine order despite political disarray (Pharmaceutical Technology) +9.26%
07:30AM	Emergent BioSolutions Receives New Contract Modification for ACAM2000, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness (GlobeNewswire)
Sep-02-25 07:40AM	Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use (GlobeNewswire)
Aug-29-25 08:05AM	Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day (GlobeNewswire)
Aug-27-25 08:01AM	Emergent BioSolutions to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-21-25 08:45AM	Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day (GlobeNewswire)
Aug-18-25 09:45AM	Big Rallies Brewing? 3 Analyst Favorites to Watch Closely (MarketBeat)
Aug-07-25 10:16AM	Influenza Vaccine Market Research Report 2025-2030 Featuring GSK, Abbott, Pfizer, AstraZeneca, Sanofi, Moderna, CSL, Emergent BioSolutions, BIKEN, Serum Institute of India, Sinovac, GC Biopharma (GlobeNewswire) +36.65%
Aug-06-25 05:22PM	Emergent Biosolutions: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	Emergent BioSolutions Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-28-25 08:50AM	New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox (GlobeNewswire) -5.44%
08:50AM	Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives (GlobeNewswire)
Jul-15-25 07:30AM	Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire) -5.07%
Jul-08-25 04:45PM	Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016 [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts (GlobeNewswire) +6.70%
Jul-02-25 04:05PM	Emergent BioSolutions Expands NARCANDirect to Offer KLOXXADO (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate (GlobeNewswire) +7.73%
Jun-23-25 08:05AM	Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Bolster U.S. Biodefense Supply (GlobeNewswire)
Jun-20-25 08:13AM	Emergent BioSolutions Announces Addition to Russell 3000 Index (GlobeNewswire)
Jun-05-25 07:00AM	Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies (GlobeNewswire)
May-29-25 09:55AM	5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost (Zacks)
May-19-25 09:43AM	Zacks.com featured highlights include BrightSpring Health Services, Beyond, Air Canada, HF Sinclair and Emergent BioSolutions (Zacks)
May-16-25 10:52AM	5 Broker-Loved Stocks to Watch Amid Signs of Easing Trade Woes (Zacks) +20.95%
May-14-25 07:32AM	Emergent BioSolutions to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-08-25 09:53AM	Q1 2025 Emergent BioSolutions Inc Earnings Call (Thomson Reuters StreetEvents) +34.18%
03:33AM	Emergent BioSolutions Inc (EBS) Q1 2025 Earnings Call Highlights: Strong Net Income Growth Amid ... (GuruFocus.com)
May-07-25 10:03PM	Emergent biosolutions reaffirms 2025 revenue guidance of $750M-$850M amid turnaround progress (Seeking Alpha)
10:01PM	Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:35PM	Emergent Biosolutions (EBS) Q1 Earnings Top Estimates (Zacks)
04:32PM	Emergent Biosolutions: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Emergent BioSolutions Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 05:07PM	Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health (GlobeNewswire) -7.87%
Apr-22-25 08:00AM	Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire)
Apr-10-25 09:52AM	Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last? (Zacks) -9.17%
Apr-09-25 08:45AM	JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell? (Zacks) +9.58%
Apr-08-25 12:24AM	XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist (Seeking Alpha)
Mar-31-25 08:00AM	Emergent BioSolutions Announces Stock Repurchase Program (GlobeNewswire)
Mar-26-25 10:32AM	Emergent BioSolutions: I See Further Downside Ahead In This Value Trap (SeekingAlpha) -6.00%
Mar-20-25 04:30PM	Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 (GlobeNewswire)
08:30AM	Emergent BioSolutions: Attractive Biotech With Proven Business Clouded By Washington Funding Issues (SeekingAlpha)
08:06AM	Hikma announces Health Canada approval of KLOXXADO (naloxone HCl) Nasal Spray 8 mg (GlobeNewswire)
Mar-19-25 05:01PM	Emergent BioSolutions closes sale of Bayview facility to Syngene (SeekingAlpha)
04:30PM	Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International (GlobeNewswire)
Mar-18-25 08:00AM	Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products (GlobeNewswire)
Mar-13-25 11:00AM	Emergent signs financial investment agreement with Swiss Rockets (Pharmaceutical Technology) -10.41%
08:29AM	Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs (GlobeNewswire)
Mar-12-25 08:00AM	Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates (GlobeNewswire) +11.21%

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company's Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

M.B.A.Mr. Joseph C. Papa Jr.

Executive VP & CFOMr. Richard S. Lindahl M.B.A.

Executive Vice President of QualityMs. Coleen Glessner

Senior Vice President of Products BusinessMr. Paul A. Williams

Chief Medical Officer and Head of Research & DevelopmentMr. Simon C. Lowry M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dayal Sujata Tyagi	Director	May 01 '26	Sale	8.40	13,761	115,610	100,563	May 04 05:30 PM
DeGolyer Donald W	Director	May 01 '26	Sale	8.40	15,481	129,994	129,721	May 04 05:30 PM
Katkin Keith	Director	Apr 30 '26	Sale	8.28	15,481	128,183	96,294	May 04 05:29 PM
Zoon Kathryn C	Director	May 01 '26	Sale	8.40	17,202	144,453	79,941	May 04 05:28 PM
SUJATA TYAGI DAYAL	Director	May 01 '26	Proposed Sale	8.40	13,761	115,612		May 01 04:20 PM
KATHRYN ZOON	Director	May 01 '26	Proposed Sale	8.40	17,202	144,492		May 01 04:03 PM
DONALD DEGOLYER	Director	May 01 '26	Proposed Sale	8.40	15,481	130,064		May 01 04:02 PM
KEITH KATKIN	Director	Apr 30 '26	Proposed Sale	8.28	15,481	128,141		Apr 30 04:11 PM
Williams Paul Anthony	SVP, Products Business	Apr 01 '26	Sale	8.44	4,000	33,760	62,681	Apr 03 04:05 PM
PAUL WILLIAMS	Officer	Apr 01 '26	Proposed Sale	8.44	4,000	33,778		Apr 01 04:07 PM
LOUIS W SULLIVAN	Director	Jan 07 '26	Proposed Sale	13.99	25,748	360,142		Jan 07 04:27 PM
LOUIS W SULLIVAN	Director	Dec 22 '25	Proposed Sale	12.77	104,695	1,336,463		Dec 22 06:22 PM
Richard Ronald	Director	Dec 05 '25	Option Exercise	5.02	25,748	129,255	124,165	Dec 09 06:01 PM
Richard Ronald	Director	Dec 05 '25	Sale	11.97	21,984	263,077	98,417	Dec 09 06:01 PM
RONALD RICHARD	Director	Dec 05 '25	Proposed Sale	11.94	32,848	392,335		Dec 05 04:04 PM
DeGolyer Donald W	Director	Nov 10 '25	Sale	10.54	17,801	187,623	119,858	Nov 12 04:13 PM
Dayal Sujata Tyagi	Director	Nov 07 '25	Sale	10.00	8,552	85,520	88,980	Nov 10 04:09 PM
DONALD DEGOLYER	Director	Nov 10 '25	Proposed Sale	10.54	17,801	187,544		Nov 10 04:06 PM
SUJATA TYAGI DAYAL	Director	Nov 07 '25	Proposed Sale	10.00	8,552	85,520		Nov 07 04:02 PM
Glessner Coleen	EVP, Quality & Ethics, and CPL	Oct 07 '25	Sale	10.00	30,608	306,080	144,319	Oct 16 04:21 PM
COLEEN GLESSNER	Officer	Oct 07 '25	Proposed Sale	10.00	30,608	306,080		Oct 07 04:11 PM
Zoon Kathryn C	Director	Aug 15 '25	Sale	8.87	7,086	62,853	71,799	Aug 18 04:33 PM
KATHRYN ZOON	Director	Aug 15 '25	Proposed Sale	8.87	7,086	62,853		Aug 15 04:04 PM
DeGolyer Donald W	Director	Aug 12 '25	Sale	8.65	7,844	67,831	137,659	Aug 13 04:22 PM
DONALD DEGOLYER	Director	Aug 12 '25	Proposed Sale	8.65	7,844	67,831		Aug 12 04:06 PM

Open in Screener

APVO

Aptevo Therapeutics Inc

May 26 • 04:00PM ET

4.89

-0.06 -1.21 %

Healthcare • Biotechnology • USA • Nano • NASD

APVO Aptevo Therapeutics Inc daily Stock Chart

Peers: IMNN SABS TNXP ONCO BCDA

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-203.74	Insider Own	0.06%	Shs Outstand	1.25M	Perf Week	5.62%
Market Cap	6.10M	Forward P/E	-	EPS next Y	-21.46	Insider Trans	0.00%	Shs Float	1.25M	Perf Month	0.41%
Enterprise Value	-4.01M	PEG	-	EPS next Q	-6.41	Inst Own	6.05%	Short Float	7.38%	Perf Quarter	-28.92%
Income	-27.92M	P/S	-	EPS this Y	72.35%	Inst Trans	2.79%	Short Ratio	1.79	Perf Half Y	-74.85%
Sales	0.00M	P/B	0.51	EPS next Y	11.07%	ROA	-197.08%	Short Interest	0.09M	Perf YTD	-48.14%
Book/sh	9.65	P/C	0.42	EPS next 5Y	38.04%	ROE	-549.01%	52W High	235.98 -97.93%	Perf Year	-95.07%
Cash/sh	11.66	P/FCF	-	EPS past 3/5Y	- 89.05%	ROIC	-183.81%	52W Low	3.80 28.68%	Perf 3Y	-100.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.69% 6.70%	Perf 5Y	-100.00%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	99.36%	Oper. Margin	-	ATR (14)	0.35	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.36	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	50.18	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.36	EPS Q/Q	99.60%	SMA20	0.24%	Beta	1.68	Target Price	21.00
Payout	-	Debt/Eq	0.38	Sales Q/Q	-	SMA50	3.27%	Rel Volume	0.40	Prev Close	4.95
Employees	36	LT Debt/Eq	0.30	Earnings	Mar 26 BMO	SMA200	-70.23%	Avg Volume	51.44K	Price	4.89
IPO	Jul 20, 2016	Option/Short	No / Yes	EPS/Sales Surpr.	28458.08% -	Trades		Volume	20,525	Change	-1.21%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-05-18	Initiated	Ladenburg Thalmann	Buy
Oct-05-17	Resumed	Piper Jaffray	Overweight	$6

May-13-26 08:05AM	Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection (ACCESSWIRE)
May-06-26 08:05AM	Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection (ACCESSWIRE) -7.66%
Mar-26-26 08:05AM	Aptevo Provides State of the Business Report and 2025 Financial Results (ACCESSWIRE)
Mar-19-26 08:05AM	Aptevo to Participate in March 2026 Conferences (ACCESSWIRE)
Mar-10-26 08:05AM	Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50% (ACCESSWIRE) -22.79%
08:05AM	Loading…
Feb-03-26 08:05AM	Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth (ACCESSWIRE) -10.34%
Jan-09-26 08:05AM	Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality (ACCESSWIRE) +5.00%
Dec-26-25 08:05AM	Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split (ACCESSWIRE) -34.73%
Dec-09-25 08:05AM	Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025 (ACCESSWIRE) -7.46%
Nov-19-25 09:55AM	Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks) -7.58%
Nov-10-25 08:05AM	Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors (ACCESSWIRE) +6.12%
Nov-06-25 08:05AM	Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update (ACCESSWIRE)
Oct-08-25 08:20AM	Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter (ACCESSWIRE)
Sep-16-25 08:30AM	Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML (ACCESSWIRE)
Sep-04-25 08:45AM	Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules (ACCESSWIRE)
08:05AM	Loading…
Aug-13-25 08:05AM	Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer (ACCESSWIRE) -7.28%
Aug-11-25 08:05AM	Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update (ACCESSWIRE)
Jul-15-25 04:57PM	Aptevo Meets Nasdaq $2.5M Equity Requirement (Insider Monkey)
Jun-21-25 09:00AM	Aptevo announces addition of preclinical candidate APVO455 to portfolio (TipRanks)
Jun-20-25 11:30AM	Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -18.71%
08:55AM	Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers (ACCESSWIRE)
Jun-18-25 10:52AM	Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) +81.91%
08:01AM	Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML (ACCESSWIRE)
Jun-13-25 08:05AM	Aptevo Participating in the BIO International Convention (ACCESSWIRE) -8.16%
May-22-25 08:05AM	Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan (ACCESSWIRE) -21.05%
May-15-25 08:05AM	Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig (ACCESSWIRE)
May-08-25 08:45AM	Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation (ACCESSWIRE) -7.69%
Apr-22-25 04:05PM	Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) +9.08% +6.72%
Apr-21-25 02:40PM	Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -26.24%
Apr-04-25 04:05PM	Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -25.13% -6.71%
08:50AM	Loading…
Apr-03-25 08:50AM	Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) +44.20%
Mar-20-25 02:26PM	Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment (Benzinga) -6.09%
08:35AM	RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment (ACCESSWIRE)
Mar-18-25 08:05AM	Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy (ACCESSWIRE)
Mar-06-25 08:00AM	Aptevo to Participate in March Conferences (ACCESSWIRE)
Feb-15-25 06:59PM	Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESS Newswire)
Feb-14-25 08:05AM	Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update (ACCESSWIRE) -8.24%
Jan-15-25 08:00AM	Aptevo's Peter Pavlik, PhD, Chairing Session on 'Bi and Multispecific Biologics' at Cambridge Healthcare Institute's Pep Talk 2025 (ACCESSWIRE)
Dec-12-24 12:50PM	Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds (ACCESSWIRE) -43.76%
09:00AM	100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial (ACCESSWIRE)
Dec-04-24 08:35AM	Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects (ACCESSWIRE) +15.01%
Nov-29-24 09:55AM	Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan (ACCESSWIRE) -18.88%
Nov-26-24 08:35AM	Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation (ACCESSWIRE) +9.20%
Nov-22-24 08:35AM	Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm (ACCESSWIRE) +15.33%
Nov-20-24 08:35AM	First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies (ACCESSWIRE) +16.05%
Nov-11-24 08:15AM	First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial (ACCESSWIRE)
Nov-07-24 08:05AM	Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update (ACCESSWIRE) +19.77%
Oct-29-24 08:05AM	Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024 (ACCESSWIRE) +27.95%
Sep-18-24 04:05PM	Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -19.55% +6.93%
Sep-16-24 08:05PM	Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -7.02% -38.00%
08:20AM	Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study (ACCESSWIRE)
08:05AM	Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study (ACCESSWIRE)
Sep-13-24 08:20AM	Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024 (ACCESSWIRE)
08:05AM	Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024 (ACCESSWIRE)
Aug-13-24 08:05AM	Phase 1b/2 'RAINIER' Frontline Acute Myeloid Leukemia (AML) Trial Initiated (ACCESSWIRE) -8.57%
Aug-08-24 08:05AM	Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update (ACCESSWIRE)
Jul-01-24 04:20PM	Aptevo Therapeutics Announces Closing of $2.75 Million Offering (ACCESSWIRE) +9.15% -10.78%
Jun-28-24 09:20AM	Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -40.57%
Jun-17-24 07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -20.53%
Jun-03-24 08:05AM	Aptevo Participating in the BIO International Convention (ACCESSWIRE) +10.58%
May-14-24 08:05AM	Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA (ACCESSWIRE)
May-08-24 12:54PM	APVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -11.64%
08:05AM	Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update (ACCESSWIRE)
May-02-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +17.71%
Apr-16-24 12:47PM	Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why (Zacks)
Apr-15-24 04:05PM	Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering (ACCESSWIRE) -7.35%
Apr-11-24 08:15AM	Why Is Aptevo Therapeutics (APVO) Stock Down 56% Today? (InvestorPlace) -60.08%
08:00AM	Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering (ACCESSWIRE)
Apr-10-24 09:00AM	Aptevo Therapeutics Provides Pipeline Update (ACCESSWIRE) -26.38%
Mar-18-24 06:00AM	Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference (ACCESSWIRE) -8.12%
Mar-07-24 08:55AM	Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4 (ACCESSWIRE)
Mar-05-24 01:51PM	APVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -8.55%
08:05AM	Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update (ACCESSWIRE)
Mar-04-24 09:00AM	Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan (ACCESSWIRE) -13.72%
Nov-14-23 08:05AM	Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update (ACCESSWIRE) +6.82%
Nov-01-23 07:45AM	Aptevo to Present at Bio-Europe Conference (ACCESSWIRE)
Aug-10-23 08:05AM	Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update (ACCESSWIRE) -9.68%
Aug-06-23 07:14AM	10 Oversold Value Stocks To Buy (Insider Monkey)
Aug-04-23 06:40PM	Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering (ACCESSWIRE) -10.19%
Aug-01-23 10:15PM	Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering (ACCESSWIRE) -5.77% -38.30%
Jul-30-23 02:17PM	7 Millionaire-Maker Penny Stocks to Buy Before the Window Closes (InvestorPlace)
Jul-18-23 08:05AM	Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML (ACCESSWIRE) -23.24%
May-11-23 08:05AM	Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update (ACCESSWIRE)
Apr-01-23 08:51AM	Aptevo Therapeutics Full Year 2022 Earnings: EPS Beats Expectations (Simply Wall St.)
Mar-30-23 07:45AM	Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update (ACCESSWIRE)
07:30AM	Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding (ACCESSWIRE)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey) +6.88%
Mar-03-23 06:57PM	The Top 7 Growth Stocks in Biotech (InvestorPlace)
Feb-13-23 08:05AM	Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial (ACCESSWIRE)
Jan-09-23 08:05AM	Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors (ACCESSWIRE) +6.42%
Dec-12-22 09:54AM	Aptevo Stock Jumps As Acute Myeloid Leukemia Combo Therapy Achieves 100% Clinical Benefit Rate (Benzinga) +12.58%
07:35AM	100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML) (ACCESSWIRE)
Nov-10-22 08:05AM	Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights (ACCESSWIRE)
Nov-09-22 08:05AM	Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics (ACCESSWIRE)
Nov-03-22 09:06AM	Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition (ACCESSWIRE)
Sep-19-22 08:45AM	Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND (ACCESSWIRE)
Aug-11-22 08:05AM	Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights (ACCESSWIRE)
Jun-09-22 08:05AM	Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia (ACCESSWIRE) -14.44%
May-12-22 08:05AM	Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights (ACCESSWIRE) +11.26%
Apr-12-22 08:05AM	APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting (ACCESSWIRE)

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.

Executive ChairMr. Marvin L. White

CEOMr. Jeffrey G. Lamothe CA

LL.M.Ms. SoYoung Kwon J.D.

Senior VP & CFOMs. Daphne L. Taylor CPA

Vice President of Investor Relations & Corporate CommunicationsMs. Miriam Weber Miller

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Grant Grady III	Director	Nov 10 '25	Buy	1.49	13,513	20,134	13,514	Nov 12 04:33 PM

EBS

Emergent Biosolutions Inc

APVO

Aptevo Therapeutics Inc

Upgrade your Finviz experience